Brief: Crossject partners with Xi'an Xintong Pharmaceutical Research

Crossject SA

09/12/2015 07:01

Dec 9 (Reuters) - Crossject SA  ALCJ.PA : 
    * Announces partnership agreement for Zeneo Methotrexate in 
China with Xi'an Xintong Pharmaceutical Research 
    * Non-exclusive agreement includes milestone payment of 3 
million euros ($3.3 million) at marketing authorization 
    * Non-exclusive agreement includes payment of royalties 
representing 25 pct of sales 
    * Non-exclusive agreement includes mid-term sales 
commitments of 58 million euros for this product in year three 
after market approval 
    * Marketing authorization filing in China is expected in 
early 2017 
 
 
Source text for Eikon:  ID:nHUG1F5mwP  
Further company coverage:  ALCJ.PA  
 
($1 = 0.9152 euros) 
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))